To evaluate whether the effect of protease proprotein convertase subtilisin/kexin type 9 (PCSK9) on vascular homeostasis may be mediated by in vivo circulating endothelial progenitor cells (EPCs) in patients with or without type 2 diabetes mellitus (T2DM). Eighty- two patients (45 with, 37 without T2DM) at high cardiovascular risk were enrolled in this observational study. Plasma PCSK9 was meas- ured by ELISA and EPCs with phenotype CD45neg/CD34bright and CD34bright/CD146neg were analyzed by a standardized flow cytometry method. Statin treatment was associated with higher cir- culating levels of PCSK9 in patients with and without T2DM (p<0.001 and p=0.036) and with reduced CD45neg/CD34bright (p=0.016) and CD45neg/CD34bright/CD146neg (p=0.040) only among pa- tients with T2DM. PCSK9 correlated inversely with both CD45neg/ CD34bright (p=0.006) and CD45neg/CD34bright/CD146neg (p=0.002) only in patients with T2DM. Dividing patients according to statin treatment, PCSK9 correlated inversely with CD45neg/CD- 34bright (p=0.022) and CD45neg/CD34bright/CD146neg (p=0.004) only in patients with diabetes on statin treatment. In high-risk T2DM patients, high endogenous levels of PCSK9 may have a detrimental effect on EPCs by reducing the endothelial repair and worsening the progression of atherothrombosis.
Endogenous PCSK9 may influence circulating CD45NEG/CD34BRIGHT and CD45NEG/CD34BRIGHT/CD146NEG cells in patients with type 2 Diabetes Mellitus
223. Simeone PGM;Tripaldi R;Lanuti P;Liani R;Bologna G;Ciotti S;Simeone P;Marchisio M;Bucci M;Cipollone F;Santilli F.
2020-01-01
Abstract
To evaluate whether the effect of protease proprotein convertase subtilisin/kexin type 9 (PCSK9) on vascular homeostasis may be mediated by in vivo circulating endothelial progenitor cells (EPCs) in patients with or without type 2 diabetes mellitus (T2DM). Eighty- two patients (45 with, 37 without T2DM) at high cardiovascular risk were enrolled in this observational study. Plasma PCSK9 was meas- ured by ELISA and EPCs with phenotype CD45neg/CD34bright and CD34bright/CD146neg were analyzed by a standardized flow cytometry method. Statin treatment was associated with higher cir- culating levels of PCSK9 in patients with and without T2DM (p<0.001 and p=0.036) and with reduced CD45neg/CD34bright (p=0.016) and CD45neg/CD34bright/CD146neg (p=0.040) only among pa- tients with T2DM. PCSK9 correlated inversely with both CD45neg/ CD34bright (p=0.006) and CD45neg/CD34bright/CD146neg (p=0.002) only in patients with T2DM. Dividing patients according to statin treatment, PCSK9 correlated inversely with CD45neg/CD- 34bright (p=0.022) and CD45neg/CD34bright/CD146neg (p=0.004) only in patients with diabetes on statin treatment. In high-risk T2DM patients, high endogenous levels of PCSK9 may have a detrimental effect on EPCs by reducing the endothelial repair and worsening the progression of atherothrombosis.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
